Table 3.

Pathologic and clinical descriptions of 37 tumor samples assessed for PD-1/PD-L1 interaction scores (n=36) and CD4/CD8 T cell infiltrates (n=29).

Sample ID	PNS Type	Specimen Type	Anatomic site	Treatment naïve specimen?	PFS (months)	OS (months)	Maximum Tumor PD-L1 (%)	PD-1/PD-L1 interaction score	% CD3 +	% CD4 +	% CD8 +
1	Endocrinologic	Cytology	Primary tumor	Yes	5	Unknown	0%	0	NA	NA	NA
2	Endocrinologic	Cytology	Primary tumor	Yes	3	12	0%	0	NA	NA	NA
3	Endocrinologic	Cytology	Pleural fluid	Yes	4	5	1%	21	NA	NA	NA
4	Endocrinologic	Cytology	Primary tumor	Yes	1	8	0%	0	NA	NA	NA
5	Endocrinologic	Cytology	Primary tumor	Yes	22	24a	1%	0	NA	NA	NA
6	Endocrinologic	Cytology	Mediastinal LN	Yes	1	9b	2%	52	NA	NA	NA
7	Endocrinologic	Cytology	Mediastinal LN	Yes	1	9b	8%	36	NA	NA	NA
8	Endocrinologic	Cytology	Mediastinal LN	Yes	1	9b	1%	1	NA	NA	NA
9	Endocrinologic	Core Bx	Primary tumor	Yes	5	Unknown	0%	0	2.4	0.55	0.67
10	Endocrinologic	Core Bx	Primary tumor	No	22	24a	0%	0	0.62	0.03	0.16
11	Endocrinologicc	Core Bx	Primary tumor	No	9	14	0%	0	0.12	0.05	0.04
12	Neurologic	Core Bx	Mediastinal LN	Yes	Unknown	Unknown	51%	2535	13.9	2.85	2.43
13	Neurologic	Core Bx	Supraclavicular LN	Yes	Unknown	Unknown	23%	1665	10.6	6.22	2.74
14	Neurologic	Core Bx	Cervical LN	Yes	2	3	16%	16	0.64	0.31	0.19
15	Neurologic	Cytology	Mediastinal LN	Yes	4	5	0%	0	NA	NA	NA
16	Neurologic	Cytology	Mediastinal LN	Yes	>24	>24	33%	150	NA	NA	NA
17	Neurologic	Core Bx	Mediastinal LN	Yes	12	>16	79%	810	13.1	9.00	3.10
18	Neurologic	Core Bx	Primary tumor	Yes	12	16	6%	293	12.8	2.92	2.74
19	Neurologic	Core Bx	Mediastinal LN	Yes	23	38	72%	1367	23.8	10.10	2.10
20	Neurologic	Core Bx	Primary tumor	Yes	4	9	0%	33	1.58	0.32	0.49
21d	Neurologic	Core Bx	Mediastinal LN	Yes	18	24	34%	506	12.9	6.40	3.30
22	None	Core Bx	Primary tumor	Yes	1.5	9	0%	0	2.0	0	2.00
23	None	Core Bx	Primary tumor	Yes	9	10	0%	0	2.0	3.00	4.00
24	None	Core Bx	Primary tumor	Yes	4	12	52%	2062	14.0	20.00	6.00
25	None	Core Bx	Primary tumor	Yes	6	18	0%	454	6.0	3.00	4.00
26	None	Core Bx	Primary tumor	Yes	10	20	NA	NA	1.0	0	0
27	None	Core Bx	Primary tumor	Yes	6	16	95%	0	2.0	1.00	2.00
28	None	Core Bx	Bone	No	6	16	78%	59	3.0	3.00	2.00
29	None	Core Bx	Liver	No	8	12	3%	64	1.0	1.00	1.00
30	None	Core Bx	Pleura	Yes	3	14	9%	423	5.0	3.00	2.00
31	None	Core Bx	Bone	No	11	17	1%	0	0	0	0
32	None	Core Bx	Primary tumor	Yes	10	13	65%	726	3.0	3.00	2.00
33	None	Core Bx	Liver	Yes	8	16	0%	220	1.0	1.00	0
34	None	Core Bx	Bone	No	9	12	21%	1510	1.0	2.00	1.00
35	None	Core Bx	Primary tumor	Yes	8	17	11%	391	0	0	0
36	None	Core Bx	Primary tumor	Yes	9	14	3%	457	3.0	2.00	1.00
37	None	Core Bx	Primary tumor	Yes	8	10	1%	27	2.0	2.00	1.00

^asame patient

^bsame patient

^cpatient was treated with linsitinib at the time of diagnosis of endocrinologic paraneoplastic syndrome

^ddexcluded from cumulative analysis due to low TTF-1 staining.

Unknown: lost to follow-up; NA: not assessed; C: cytology; SP: surgical pathology; LN: lymph node; PFS: progression free survival; OS: overall survival.